Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib + Trastuzumab in Relapsing HER2+ Breast Cancer
NCT01132664Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of buparlisib in HER2-positive breast cancer, sponsored by Novartis. Started May 2010; status: terminated.
02
Drugs
buparlisib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01132664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132664.